SG/CALL/VERTEX PHARMACEUTICALS/480/0.1/20.09.24

SG/CALL/VERTEX PHARMACEUTICALS/480/0.1/20.09.24 Share Price

DE000SU6C396

Market Closed - Boerse Frankfurt Warrants 01:17:02 01/06/2024 am IST
2 ^EUR	+31.58%

Current month	+160.00%
1 month	+160.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/CALL/VERTEX PHARMACEUTICALS/480/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	30/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT

More news

Quotes 5-day view

Date	Price	Change
31/24/31	1.82	+19.74%
30/24/30	1.52	-3.18%
29/24/29	1.57	-10.29%
28/24/28	1.75	-13.79%
27/24/27	2.03	+3.57%

Real-time Boerse Frankfurt Warrants

Last update May 01, 2024 at 01:17 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SU6C39
ISIN	DE000SU6C396
Date issued	28/12/2023
Strike	480 $
Maturity	20/09/2024 (111 Days)
Parity	10 : 1
Emission price	1.89 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	3.17 €
Lowest since issue	0.6 €
Delta	0.44x
Omega	9.351
Premium	10.12x
Gearing	21.25x
Moneyness	0.9486
Difference Strike	24.66 $
Difference Strike %	+5.14%
Spread	0.03 €
Spread %	1.51%
Theoretical value	1.995
Implied Volatility	28.56 %
Total Loss Probability	62.05 %
Intrinsic value	0.000000
Present value	1.995
Break even	501.64 €
Theta	-0.1x
Vega	0.09x
Rho	0.05x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company